Search Results

Credence MedSystems announced that it has successfully completed Factory Acceptance Testing for production of its Companion® injection device platform on the Company’s new Clinical Assembly Line.

Credence MedSystems, Inc. announced today that it has formed a strategic collaboration with Phillips-Medisize, a Molex company, a global leader in the design and manufacturing of solutions for the pharmaceutical drug delivery market.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company.

Credence MedSystems, Inc. announced today that it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG, Molex Ventures LLC as well as additional investors.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.

Relievant Medsystems today announced the release of next-generation Intracept ® Access Instruments.

Credence MedSystems and SCHOTT AG have formed a collaboration for the application of Credence Companion® technology with SCHOTT’s pre-fillable syriQ® glass and SCHOTT TOPPAC® polymer syringe systems.

Novartis has invested in Credence, confirming its interest in employing Credence technology for its injectable medicines. The investment is geared towards supporting Credence’s ramp-up of manufacturing capacity for its innovative drug delivery systems and enabling commercial supply of Credence devices to the pharmaceutical market.

Relievant Medsystems announced the publication of a pooled analysis from three prospective clinical trials that demonstrates the impact of the company’s Intracept® Procedure on significantly reducing the long-term utilization of additional treatments for low back pain.